

PORTOLA PHARMACEUTICALS INC
 Form 4
 December 10, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Fullerton Management Pte Ltd

2. Issuer Name and Ticker or Trading Symbol
 PORTOLA PHARMACEUTICALS INC [PTLA]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 60B ORCHARD ROAD #06-18,
 TOWER 2, THE
 ATRIUM@ORCHARD
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 12/09/2015

____ Director
 ____ Officer (give title below)
 10% Owner
 ____ Other (specify below)

SINGAPORE, U0 238891
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ____ Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	12/09/2015		P		750,000	A	\$ 48
					6,583,568	I	

See footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Beneficially (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Fullerton Management Pte Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891		X		
Temasek Holdings (Private) Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891		X		

Signatures

/s/ Christina Choo, Authorised Signatory, Temasek Holdings (Private) Limited
 **Signature of Reporting Person
 Date 12/10/2015

/s/ Cheong Kok Tim, Director, Fullerton Management Pte Ltd
 **Signature of Reporting Person
 Date 12/10/2015

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Fullerton Management Pte Ltd ("FMPL") indirectly owns 6,583,568 shares of the Issuer's common stock ("Shares") through two indirect wholly-owned subsidiaries, V-Sciences Investments Pte Ltd ("V-Sciences") which owns 750,000 Shares and Maxwell (Mauritius) Pte Ltd ("Maxwell") which owns 5,833,568 Shares. V-Sciences is wholly-owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. Maxwell is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd which is wholly owned by FMPL. FMPL is wholly-owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of common stock owned by V-Sciences and Maxwell, collectively.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: PORTOLA PHARMACEUTICALS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.